Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

Fig. 3

ctDNA PTPRD mutation predict the efficiency of ICIs in ns-NSCLC. a, b Progression-free survivals of NSCLC (a) or ns-NSCLC (b) in validation cohort 3. c, d Objective responses of NSCLC (c) or ns-NSCLC (d) in different groups. e, f Overall survivals of NSCLC (e) or ns-NSCLC (f) in validation cohort 3

Back to article page